Allarity therapeutics takes decisive step toward regaining nasdaq compliance with nasdaq listing rule 5550(a)(2)

Boston (september 11, 2024) — allarity therapeutics, inc. (“allarity” or the “company”) (nasdaq: allr), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the company is taking a decisive step toward regaining compliance with nasdaq's listing requirements, as outlined by the nasdaq hearings panel during a meeting on august 15, 2024.
NDAQ Ratings Summary
NDAQ Quant Ranking